NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$21.40

+0.41 (+1.95 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.35

Now: $21.40▼

$21.54

50-Day Range

$17.58

MA: $19.18▼

$21.69

52-Week Range

$8.80

Now: $21.40▼

$25.79

Volume1.00 million shs

Average Volume1.13 million shs

Market Capitalization$814.18 million

P/E RatioN/A

Dividend YieldN/A

Beta2.44

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

MarketRank^™

Overall MarketRank^™

1.51 out of 5 stars

Medical Sector

405th out of 1,926 stocks

Pharmaceutical Preparations Industry

207th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
G1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.17, G1 Therapeutics has a forecasted upside of 134.4% from its current price of $21.40.
Amount of Analyst Coverage
G1 Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
G1 Therapeutics has received 269 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
G1 Therapeutics has received 292 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
G1 Therapeutics has received 52.05% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote “Outperform” if you believe GTHX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
G1 Therapeutics does not currently pay a dividend.
Dividend Growth
G1 Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, G1 Therapeutics insiders have sold 176.63% more of their company's stock than they have bought. Specifically, they have bought $675,000.00 in company stock and sold $1,867,241.00 in company stock.
Percentage Held by Insiders
Only 14.49% of the stock of G1 Therapeutics is held by insiders.
Percentage Held by Institutions
77.89% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for G1 Therapeutics are expected to decrease in the coming year, from ($2.79) to ($3.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of G1 Therapeutics is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of G1 Therapeutics is -7.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
G1 Therapeutics has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GTHX

Previous Symbol

CUSIPN/A

CIK1560241

Webwww.g1therapeutics.com

Phone919-213-9835

Employees104

Debt

Debt-to-Equity Ratio0.10

Current Ratio7.45

Quick Ratio7.45

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.80 per share

Price / Book3.15

Profitability

EPS (Most Recent Fiscal Year)($3.27)

Net Income$-122,450,000.00

Net MarginsN/A

Return on Equity-49.35%

Return on Assets-41.53%

Miscellaneous

Outstanding Shares38,046,000

Market Cap$814.18 million

Next Earnings Date2/24/2021 (Estimated)

OptionableOptionable

$21.40

+0.41 (+1.95 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

How has G1 Therapeutics' stock been impacted by Coronavirus (COVID-19)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GTHX shares have increased by 47.7% and is now trading at $21.40.
View which stocks have been most impacted by COVID-19.

Is G1 Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as G1 Therapeutics' CEO?

1,448 employees have rated G1 Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among G1 Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for G1 Therapeutics.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06. The firm earned $26.60 million during the quarter, compared to the consensus estimate of $40 million.
View G1 Therapeutics' earnings history.

What price target have analysts set for GTHX?

7 analysts have issued 12 month price objectives for G1 Therapeutics' stock. Their forecasts range from $21.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $50.17 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts' price targets for G1 Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of G1 Therapeutics' key competitors?

Some companies that are related to G1 Therapeutics include Corcept Therapeutics (CORT), I-Mab (IMAB), Pacira BioSciences (PCRX), ALX Oncology (ALXO), Nektar Therapeutics (NKTR), CytoDyn (CYDY), Global Blood Therapeutics (GBT), OPKO Health (OPK), Cryoport (CYRX), Taro Pharmaceutical Industries (TARO), Rocket Pharmaceuticals (RCKT), IGM Biosciences (IGMS), Axsome Therapeutics (AXSM), Xencor (XNCR) and Karuna Therapeutics (KRTX).
View all of GTHX's competitors.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:

Ms. Jennifer K. Moses, Chief Financial Officer (Age 46, Pay $441.6k)
Dr. Mark A. Velleca, Sr. Advisor & Director (Age 57, Pay $878.21k)
Dr. Rajesh K. Malik, Chief Medical Officer and Sr. VP of R&D (Age 62, Pay $560.17k)
Mr. Mark Avagliano, Chief Bus. Officer (Age 45, Pay $559.74k)
Mr. John E. Bailey Jr., CEO, Pres & Director (Age 56)
Mr. Terry L. Murdock, Chief Operating Officer (Age 61)
Mr. Alexander D. Smith M.S., VP of Technical Operations
Dr. Jay C. Strum, Chief Scientific Officer (Age 57)
Mr. Jeff Macdonald, Sr. Director of Investor Relations & Corp. Communications
Mr. Blake Jensen, VP of Quality & Compliance

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.63%) and Pacer Advisors Inc. (0.01%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, and Pacer Advisors Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $21.40.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $814.18 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 104 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here